

SUPPLEMENTARY MATERIAL

A convenient synthesis of orthogonally protected 2-deoxystreptamine (2-DOS) as an aminocyclitol scaffold for the development of novel aminoglycoside antibiotic derivatives against bacterial resistance.

Claude Bauder

Institut de Chimie, UMR 7177 associé au CNRS - Université Louis Pasteur, 1 rue Blaise Pascal,
67000 Strasbourg, France.

E-mail: cbauder@chimie.u-strasbg.fr

This Supporting Information contains additional experimental procedures and characterization details for the intermediates **1**, **2**, **4**, **5**, **9**, **10**, **11**, **11a** and **11b**, as well as full NMR spectra for all the products described in the paper.

General Information.

Reactions were carried out in flame-dried glassware under an argon atmosphere, unless otherwise noted. All solvents used were of reagent grade. Tetrahydrofuran (THF) was freshly distilled from sodium/benzophenone under argon immediately prior to use. Unless otherwise noted, reactions were magnetically stirred and monitored by thin layer chromatography (TLC) with 0.25 mm Merck pre-coated silica gel plates. Spots were detected under UV (254 nm) and/or by staining with acidic ceric ammonium molybdate unless otherwise noted. Flash chromatography were performed with silica gel 60 (particle size 0.040-0.063 mm) supplied by Merck, Geduran. Yields refer to chromatographically and spectroscopically pure compounds, unless otherwise stated. ¹H NMR, ¹³C NMR, COSY, NOESY, HMQC as well as HMBC spectra were measured on Bruker Avance-300 spectrometer using an internal deuterium lock at ambient temperature. If not otherwise noted, CDCl₃ (7.26 ppm relative to residual CHCl₃) is the solvent for all NMR experiments. Multiplicities are described using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, ABX = an ABX system. Chemical shift are given in ppm and coupling constant are presented in Hz. ¹³C NMR spectra were calibrated from the central triplet peak, to 77.0 ppm for CDCl₃. Optical rotations [α] were recorded on a Polarimeter Model 341 (Perkin Elmer) at a wavelength of 589 nm and are reported as follows: [α]_D, concentration (*c* in g/100 mL) and solvent. Elemental analysis were collected at the Service de microanalyse of the University Louis Pasteur of Strasbourg (France).


Table of contents for experimental procedures :

Experimental procedures of compound 1	3
Experimental procedures of compound 2	3
Experimental procedures of compound 4	4
Experimental procedures of compound 5	4
Experimental procedures of compound 9	5
Experimental procedures of compound 10	6
Experimental procedures of compound 11	7
Experimental procedures of compound 11a	7
Experimental procedures of compound 11b	8
References	9

Table of contents for NMR spectra :

¹ H, ¹³ C NMR and COSY Spectra of compound 1	10
¹ H, ¹³ C NMR and COSY Spectra of compound 2	11
¹ H, ¹³ C NMR, COSY and HMQC Spectra of compound 3	13
¹ H and ¹³ C NMR Spectra of compound 4	15
¹ H, ¹³ C NMR, COSY, HMQC and HMBC Spectra of compound 5	16
¹ H, ¹³ C NMR, COSY and HMQC Spectra of compound 6	19
¹ H, ¹³ C NMR, COSY, NOESY, HMQC and HMBC Spectra of compound 7a ...	21
¹ H, ¹³ C NMR, COSY and HMQC Spectra of compound 7b	24
¹ H, ¹³ C NMR, COSY, HMQC and NOESY Spectra of compound 7c	26
¹ H, ¹³ C NMR, COSY, NOESY, HMQC and HMBC Spectra of compound 8	28
¹ H, ¹³ C NMR and COSY Spectra of compound 9	31
¹ H, ¹³ C NMR, COSY, HMQC and HMBC Spectra of compound 10	33
¹ H, ¹³ C NMR and COSY Spectra of compound 11	36
¹ H, ¹³ C NMR, COSY and HMQC Spectra of compound 11a	38
¹ H, ¹³ C NMR, COSY, NOESY and HMQC Spectra of compound 11b	40
¹ H, ¹³ C NMR, COSY, NOESY, HMQC and HMBC Spectra of compound 12	43
¹ H, ¹³ C NMR, COSY and HMQC Spectra of compound 13	46
¹ H, ¹³ C NMR, COSY and HMQC Spectra of compound 14	48
¹ H and ¹³ C NMR, Spectra of compound 14a	50
¹ H, ¹³ C NMR, COSY, NOESY, HMQC and HMBC Spectra of compound 15	51
¹ H, ¹³ C NMR, COSY, NOESY, HMQC and HMBC Spectra of compound 16	54
¹ H, ¹³ C NMR, COSY, NOESY, HMQC and HMBC Spectra of compound 17	57
¹ H, ¹³ C NMR, COSY, NOESY, HMQC and HMBC Spectra of compound 18	60
¹ H, ¹³ C NMR, COSY, NOESY, HMQC and HMBC Spectra of compound 19	63

Experimental Section :



Methyl 3,4-di-*O*-benzoyl-2,6-di-*O*-tosyl- α -D-glucopyranoside (**1**)¹


This compound **1** was synthesized from commercially available methyl α -D-glucopyranoside (21 g) according the literature¹ and obtained by simple crystallization in 92% yield (lit.^{1a} 38%). Mp = 193 °C (lit.^{1a}; 190-191 °C). $[\alpha]_D^{20} = +27.7$ (c 1.79 in CHCl₃), (lit.^{1a}; +22.5 (c 2.5 in CHCl₃)). ¹H NMR (300 MHz, CDCl₃), δ (ppm) = 7.76-6.92 (m, 18 H, Ar), 5.82 (dd, 1 H, $J_{3-2} = J_{3-4} = 9.7$ Hz, H-3), 5.27 (dd, 1 H, $J_{4-3} = J_{4-5} = 9.7$ Hz, H-4), 5.02 (d, 1 H, $J_{1-2} = 3.6$ Hz, H-1 β anomeric), 4.51 (dd, 1 H, $J_{2-1} = 3.6$ Hz, $J_{2-3} = 10$ Hz, H-2), 4.20-4.17 (m, 1 H, H-5), 4.19-4.14 (m, 1 H, H-6a), 4.05 (dd, 1 H, $J_{6b-6a} = 11.5$ Hz, $J_{6b-5} = 5.9$ Hz, H-6b), 3.46 (s, 3 H, MeO), 2.33 (s, 3 H, CH₃ of pTs at C6), 2.19 (s, 3 H, CH₃ of pTs at C2). ¹³C NMR (75 MHz, CDCl₃), δ (ppm) = 164.9 (CO), 164.8 (CO), 145.0 (Cq Ar), 144.9 (Cq Ar), 133.5 (CH Ar), 133.1 (CH Ar), 132.6 (Cq Ar), 132.2 (Cq Ar), 129.7 (CH Ar), 128.7 (Cq Ar), 128.4 (CH Ar), 128.3 (Cq Ar), 128.1 (CH Ar), 128.0 (CH Ar), 127.6 (CH Ar) (CH Ar), 97.7 (CH anomeric), 76.3 (CH), 69.4 (CH), 68.7 (CH), 67.6 (CH₂), 67.2 (CH), 56.2 (MeO), 21.6 (2 x Me of pTs).



Methyl 3,4-di-*O*-benzoyl-6-deoxy-6-iodo-2-*O*-tosyl- α -D-glucopyranoside (**2**)


This compound **2** was synthesized from **1** (10.8 g) according the literature^{1a,2} and obtained by simple crystallization in 93% yield (lit.^{1a}; 88 %). Mp = 180 °C (lit.^{1a}; 179-180 °C). $[\alpha]_D^{20} = +32.4$ (c 1.03 in CHCl₃), (lit.^{1a}; +32 (c 3 in CHCl₃)). ¹H NMR (300 MHz, CDCl₃), δ (ppm) = 7.9-6.9 (m, 14 H, Ar), 5.88 (dd, 1 H, $J_{3-2} = J_{3-4} = 9.7$ Hz, H-3), 5.19 (dd, 1 H, $J_{4-3} = J_{4-5} = 9.7$ Hz, H-4), 5.08 (d, 1 H, $J_{1-2} = 3.7$ Hz, H-1 β anomeric), 4.60 (dd, 1 H, $J_{2-1} = 3.7$ Hz, $J_{2-3} = 10.1$ Hz, H-2), 3.99 (ddd, Hx of ABX, 1 H, $J_{5-4} = 9.7$ Hz, $J_{5-6a} = 8.4$ Hz, $J_{5-6b} = 2.6$ Hz, H-5), 3.56 (s, 3 H, MeO), 3.25 (AB part on an ABX system, 2 H, $J_{AB} = 11$ Hz, $J_{AX} = 8.4$ Hz, $J_{BX} = 2.6$ Hz, $\Delta\nu = 48$ Hz, H-6), 2.20 (s, 3 H, CH₃ of pTs). ¹³C NMR (75 MHz, CDCl₃), δ (ppm) = 165.2 (CO), 164.9 (CO), 144.9 (Cq Ar), 133.7 (CH Ar), 133.1 (CH Ar), 132.7 (Cq Ar), 129.8 (CH Ar), 129.7 (CH Ar), 128.7 (Cq Ar), 128.4 (CH Ar), 128.3 (Cq Ar), 128.1 (CH Ar), 127.6

(CH Ar), 97.7 (CH anomeric), 72.5 (CH), 69.0 (CH), 68.9 (CH), 56.3 (MeO), 21.6 (Me of pTs), 3.2 (CH₂).



Methyl 3,4-Di-*O*-Benzoyl-6-deoxy-2-*O*-tosyl- α -D-xylo-hex-5-enopyranoside (**4**)^{1a,3}


The iodo glucopyranoside **2** (5.57 g; 8.35 mmol) and DBU (5 mL; 4 equiv.) were heated in dry PhMe (40 mL) for 15 h at ca 80 °C. The resulting deep red mixture was left at room temperature for 1 h without stirring. The upper layer was concentrated in vacuo and then diluted with CH₂Cl₂ (80 mL). The organic layer was washed with water (2 x 60 mL), sat. aq. sodium thiosulfate (50 mL), water (2 x 50 mL), brine (20 mL), dried (MgSO₄), filtered and concentrated under reduced pressure. The crude product was purified by chromatography column on silica gel (AcOEt/cyclohexane, 1:1) to yield a white powder of the title enone **4**³ (3.07 g; 68.2%, lit.^{1a}, 76%). Mp = 138 °C (lit.^{1a}, 132-3 °C). $[\alpha]_D^{20} = +23.2$ (c 1.16 in CHCl₃), (lit.^{1a}, +24 (c 1.3 in CHCl₃)). ¹H NMR (300 MHz, CDCl₃), δ (ppm) = 7.96-6.93 (m, 14 H, Ar), 5.90 (dd, 1 H, $J_{3-2} = J_{3-4} = 9.7$ Hz, H-3), 5.75 (ddd, 1 H, $J_{4-3} = 9.6$ Hz, $J_{4-6a} = J_{4-6b} = 2.1$ Hz, H-4), 5.15 (d, 1 H, $J_{1-2} = 3.4$ Hz, H-1 β anomeric), 4.85 (dd, 1 H, $J_{6a-6b} = J_{6a-4} = 2.1$ Hz, H-6a), 4.73 (dd, 1 H, $J_{2-1} = 3.4$ Hz, $J_{2-3} = 9.8$ Hz, H-2), 4.66 (dd, 1 H, $J_{6b-6a} = J_{6b-4} = 2.1$ Hz, H-6b), 3.53 (s, 3 H, MeO), 2.20 (s, 3 H, CH₃ of pTs). ¹³C NMR (75 MHz, CDCl₃), δ (ppm) = 165.0 (CO), 164.8 (CO), 149.3 (Cq Ar), 145.0 (Cq Ar), 133.6 (CH Ar), 133.1 (CH Ar), 132.7 (Cq Ar), 129.9 (CH Ar), 129.7 (2 x CH Ar), 128.8 (Cq Ar), 128.6 (Cq Ar), 128.5 (CH Ar), 128.1 (CH Ar), 127.6 (CH Ar), 98.6 (CH anomeric), 98.5 (CH₂ vinyl), 76.4 (CH), 69.8 (CH), 69.3 (CH), 56.1 (MeO), 21.6 (Me of pTs).



Preparation of the cyclohexanone (**5**)^{1a,4}


To the enone **4** (0.653 g; 1.21 mmol) dissolved in acetone (40 mL) and water (15 mL) were added successively Hg(OAc)₂ (680 mg; 1.7 equiv.) and AcOH (5 mL). The medium turned quickly from yellow to colorless and the reaction was heated for 2.5 h at 70 °C. The organic solvent was then evaporated in vacuo and CH₂Cl₂ (60 mL) was added to the aqueous residue. The organic layer was filtered on a pad of Celite and rinsed with CH₂Cl₂ (2 x 10 mL). The

combined organic layers were washed with water (3 x 15 mL), aq. sat. NaHCO₃ (2 x 15 mL), water (3 x 15 mL), dried (MgSO₄), filtered and the solvent was concentrated to the half of its volume. The desired product crystallized slowly to give white needles of the β-hydroxyketone **5** (0.440 g; 69%). Mp = 178 °C (lit.^{1a}, 175-6 °C). [α]_D²⁰ = -21.1 (c 1.08; CHCl₃). ¹H NMR (300 MHz, CDCl₃), δ (ppm) = 7.96-6.92 (m, 14 H, Ar), 6.13 (dd, 1 H, *J*₃₋₂ = *J*₃₋₄ = 10.1 Hz, H-3), 5.67 (d, 1 H, *J*₄₋₃ = 10.4 Hz, H-4), 5.12 (dd, 1 H, *J*₂₋₃ = 9.8 Hz, *J*₂₋₁ = 2.5 Hz, H-2), 4.72 (m, X of an ABX system, 1 H, H-1), 2.79 (s br, 1H, OH), 2.88 (AB part on an ABX system, 2 H, *J*_{AB} = 15.1 Hz, *J*_{AX} = 3.7 Hz, *J*_{BX} = 2.7 Hz, Δ*v* = 34 Hz, H-6), 2.18 (s, 3 H, CH₃ of pTs). ¹³C NMR (75 MHz, CDCl₃), δ (ppm) = 195.8 (CO), 165.4 (Cq COOBz), 164.5 (Cq COOBz), 145.2 (Cq Ar), 133.5 (CH Ar), 133.3 (CH Ar), 132.7 (Cq Ar), 130.0 (CH Ar), 129.9 (CH Ar), 129.8 (CH Ar), 128.6 (Cq Ar), 128.4 (CH Ar), 128.2 (CH Ar), 127.6 (CH Ar), 81.1 (CH-2), 76.9 (CH-4), 69.9 (CH-3), 68.1 (CH-1), 42.7 (CH₂-6), 21.8 (Me of pTs).



Methyl 4,6-*O*-Benzylidene-α-D-glucopyranoside (**9**)⁵


A solution of methyl α-D-glucopyranoside⁶ (19.40 g; 0.099 mol) and p-toluenesulfonic acid monohydrate (2 g; 1 equiv.) and α,α-dimethoxytoluene (15.4 mL; 1 equiv.) in dry DMF (80 mL) was refluxed at 84 °C under reduced pressure (ca 20 mbar) during 1.5 h. All the solvent was then evaporated by concentration under reduced pressure to leave a white solid product which was finely dispersed in an aqueous saturated solution of NaHCO₃ (100 mL). The mixture was stirred for 15 min at 80 °C, diluted with water (100 mL) and filtered. The white cake was washed thoroughly with water (4 x 100 mL), dried under water-aspirator vacuum for 3 h, azeotroped with benzene (3 x 100 mL) and then dried under high reduced pressure. No further purification was necessary for this white powder product of methyl 4,6-*O*-benzylidene-α-D-glucopyranoside **9** (20.6 g; 73%). Mp = 170 °C. (lit.^{5a}, 168-9 °C). [α]_D²⁰ = +104 (c 1.16 in CHCl₃), (lit.^{5a}, +105 (c 1.1 in CHCl₃)). ¹H NMR (300 MHz, CDCl₃), δ (ppm) = 7.51-7.46 (m, 2 H, Ar), 7.40-7.33 (m, 3 H, Ar), 5.52 (s, 1 H, H-7), 4.77 (d, 1 H, *J*₁₋₂ = 3.9 Hz, H-1), 4.28 (dd, 1 H, *J*_{6e-6a} = 9.1 Hz, *J*_{6e-5} = 3.7 Hz, H-6eq), 3.92 (ddd, 1 H, *J*₃₋₄ = *J*₃₋₂ = 9.3 Hz, *J*_{3-OH} = 1.8 Hz, H-3), 3.81-3.76 (m, 1 H, H-5), 3.73 (dd, 1 H, *J*_{6a-6e} = *J*_{6a-5} = 9.9 Hz, H-6ax), 3.61 (dd, 1 H, *J*₂₋₃ = *J*_{2-OH} = 9.2 Hz, *J*₂₋₁ = 3.9 Hz, H-2), 3.49 (dd, 1 H, *J*₄₋₅ = *J*₄₋₃ = 9.2 Hz, H-4), 3.44 (s, 3 H, MeO), 3.01 (d, 1 H, *J*_{OH-3} = 1.9 Hz, OH), 2.48 (d, 1 H, *J*_{OH-2} = 9.2 Hz, OH). ¹³C NMR (75 MHz, CDCl₃), δ (ppm) = 137.0 (Cq Ar), 129.3 (CH Ar), 128.3 (CH Ar), 126.3 (CH Ar), 101.9 (CH benzyl), 99.8 (CH-1), 80.9 (CH-4), 72.8 (CH-2), 71.7 (CH-3), 68.9 (CH₂), 62.3 (CH-5), 55.6 (OMe).



Methyl 4,6-*O*-Benzylidene 2-*O*-Tosyl- α -D-glucopyranoside (**10**)⁷


Method A^{7c} (with Bu₂SnO): Methyl 4,6-*O*-benzylidene- α -D-glucopyranoside **9** (4.92 g; 0.0174 mol) and Bu₂SnO (4.77 g; 1.1 equiv.) were added to a solution of toluene and methanol (36 mL : 4 mL). The mixture was heated for 3 h at 85 °C and then the solvents were removed to leave a thick solution that was diluted with toluene (40 mL). To this solution were added *p*-toluenesulfonyl chloride (6.64 g; 2 equiv.) and triethylamine (0.25 mL). After being stirred for 3.5 h at room temperature, the mixture was treated with a saturated aq. solution of NaHCO₃ (40 mL), CH₂Cl₂ (100 mL) and water (50 mL). After filtration through a pad of Celite the organic layer was dried (MgSO₄), filtered and concentrated under reduced pressure. The crude product was then purified by column chromatography on a silica gel (cyclohexane/AcOEt, 4:1 to 1:1) to afford a crystalline white solid of **10** (6.28 g; 82.3%).

Method B^{7b} (with Ts.Im): Methyl 4,6-*O*-benzylidene- α -D-glucopyranoside **9** (11.24 g; 0.0398 mol) and the *N*-tosylimidazole (13.27 g; 1.5 equiv.) were dissolved in a solution of CHCl₃-pentane (250 mL/200 mL). Sodium methanolate (3.2 g; 1.48 equiv.) was then added and the reaction was stirred at 65 °C for 3 h. After cooling the mixture was diluted with CHCl₃ (150 mL) and water (150 mL). The organic layer was washed with water (5 x 100 mL), dried (MgSO₄), filtered and concentrated under reduced pressure to give a viscous yellow liquid which was crystallized upon trituration with ethanol. Concentration of the mother liquors produced further crops of white crystals of **10** (total yield 9.60 g; 55%). Mp = 154 °C, (lit.^{7a,b,c}, 153-155 °C). $[\alpha]_{\text{D}}^{20} = +64.6$ (c 1.11 in CHCl₃), lit.^{7a}, +64 (c 1 in CHCl₃). **¹H NMR** (300 MHz, CDCl₃), δ (ppm) = 7.84 (d, 2 H, $J = 8.3$ Hz, ArCH of pTs), 7.46-7.41 (m, 2 H, Ar), 7.35-7.32 (m, 5 H, Ar), 5.48 (s, 1 H, H-7), 4.84 (d, 1 H, $J_{1-2} = 3.7$ Hz, H-1), 4.37 (dd, 1 H, $J_{2-3} = 9.3$ Hz, $J_{2-1} = 3.8$ Hz, H-2), 4.26 (dd, 1 H, $J_{6e-6a} = 9.9$ Hz, $J_{6e-5} = 4.5$ Hz, H-6eq), 4.13 (ddd, 1 H, $J_{3-4} = J_{3-2} = 9.3$ Hz, $J_{3-OH} = 3.1$ Hz, H-3), 3.81 (ddd, 1 H, $J_{5-6a} = 10.1$ Hz, $J_{5-6e} = 4.6$ Hz, $J_{5-4} = 9.6$ Hz, H-5), 3.70 (dd, 1 H, $J_{6a-6e} = J_{6a-5} = 10.1$ Hz, H-6ax), 3.46 (dd, 1 H, $J_{4-5} = J_{4-3} = 9.3$ Hz, H-4), 3.34 (s, 3 H, MeO), 2.48 (d, 1 H, $J_{OH-3} = 3.1$ Hz, OH), 2.43 (s, 3H, Me of pTs). **¹³C NMR** (75 MHz, CDCl₃), δ (ppm) = 145.2 (Cq Ar), 136.8 (Cq Ar), 133.2 (Cq Ar), 129.8 (CH Ar), 129.3 (CH Ar), 128.3 (CH Ar), 128.1 (CH Ar), 126.2 (CH Ar), 101.9 (CH benzyl), 98.2 (CH-1), 80.9 (CH), 79.5 (CH), 68.7 (CH₂), 68.3 (CH), 61.9 (CH), 55.7 (MeO), 21.7 (Me of pTs).



Methyl 3-O-Benzyl-4,6-O-benzylidene-2-O-(4-toluenesulfonyl)- α -D-glucopyranoside (11)⁸


Methyl 4,6-*O*-Benzylidene 2-*O*-Tosyl- α -D-glucopyranoside **10** (3.152 g; 0.0072 mol) in dry DMF (5 mL) was slowly added at 0 °C to a mixture containing of BaO (8.915; 8.05 equiv.) and Ba(OH)₂·8H₂O (2.315; 1.01 equiv.) in dry DMF (12 mL). Immediately after, benzylbromide (1.9 mL, 2.21 equiv.) was added at the same temperature. The reaction was then stirred 8 h at ambient temperature before addition of Celite and filtration of the mixture. The pad was washed with AcOEt (3 x 30 mL) and the combined solvents were washed with water (4 x 50 mL), brine (20 mL), dried (MgSO₄), filtered and concentrated in vacuo to get a white powder. Recrystallization (3 crops) in AcOEt/EtOH (1:2) yielded a white crystalline solid of **11** (total yield 3.31 g; 87%). Mp = 128 °C, (lit.⁸; 119-21 °C), $[\alpha]_D^{20} = +2$ (c 1.31 in CHCl₃), lit.⁸ + 4 (c 1.6 in CHCl₃). ¹H NMR (300 MHz, CDCl₃), δ (ppm) = 7.84 (d, 2 H, $J = 8.4$ Hz, ArCH of pTs), 7.35-7.32 (m, 12 H, Ar), 5.52 (s, 1 H, H-7), 4.96 (d, 1 H, $J_{1-2} = 3.8$ Hz, H-1), 4.70 and 4.50 (AB system, 2 H, $J = 11.3$ Hz, $\Delta\nu = 58.6$ Hz, PhCH₂O), 4.41 (dd, 1 H, $J_{2-3} = 9.4$ Hz, $J_{2-1} = 3.8$ Hz, H-2), 4.29 (dd, 1 H, $J_{6e-6a} = 9.9$ Hz, $J_{6e-5} = 4.5$ Hz, H-6eq), 4.00 (ddd, 1 H, $J_{3-4} = J_{3-2} = 9.3$ Hz, H-3), 3.85 (ddd, 1 H, $J_{5-6a} = 10.0$ Hz, $J_{5-6e} = 4.6$ Hz, $J_{5-4} = 9.7$ Hz, H-5), 3.72 (dd, 1 H, $J_{6a-6e} = J_{6a-5} = 10.0$ Hz, H-6ax), 3.59 (dd, 1 H, $J_{4-5} = J_{4-3} = 9.3$ Hz, H-4), 3.41 (s, 3 H, MeO), 2.37 (s, 3 H, Me of pTs). ¹³C NMR (75 MHz, CDCl₃), δ (ppm) = 144.9 (Cq Ar), 137.9 (Cq Ar), 137.1 (Cq Ar), 133.2 (Cq Ar), 129.7 (CH Ar), 129.0 (CH Ar), 128.2 (CH Ar), 128.1 (CH Ar), 128.0 (CH Ar), 127.9 (CH Ar), 127.6 (CH Ar), 126.0 (CH Ar) 101.4 (CH-7), 98.6 (CH-1), 81.9 (CH), 79.0 (CH), 75.7 (CH), 75.0 (CH₂O benzyl), 68.8 (CH₂-6), 55.7 (MeO), 21.6 (Me of pTs).



Methyl 3-O-Benzyl-4,6-O-benzylidene- α -D-glucopyranoside (11a)^{8,9}

To a solution of methyl 3-*O*-Benzyl-4,6-*O*-benzylidene-2-*O*-(4-toluenesulfonyl)- α -D-glucopyranoside **11** (2.122 g; 4.02 mmol) in dry DMSO (12 mL) was added solid NaBH₄ (2.17; 14.3 equiv.) at 0 °C (exothermic reaction). The solution was then heated to 160 °C and the reaction was stirred for 3 days (70 to 90 h). After cooling of the medium, water (50 mL) was cautiously added and stirring was continued during 2 h. The precipitate was filtered out, washed with water (30 mL) and azeotroped with benzene (3 x 10 mL) to leave a white solid

of **11a** (1.38 g; 78.1%). Mp = 184 °C, lit.⁹; 176 °C, $[\alpha]_D^{20} = +77.0$ (c 0.91 in CHCl₃), lit.⁹; +79 (c 1.2 in CHCl₃). ¹H NMR (300 MHz, CDCl₃), δ (ppm) = 7.55-7.27 (m, 10 H, Ar), 5.57 (s, 1 H, H-7), 4.96 and 4.79 (AB system, 2 H, $J = 11.4$ Hz, $\Delta\nu = 51.8$ Hz, PhCH₂O), 4.81 (d, 1 H, $J_{1-2} = 3.4$ Hz, H-1), 4.30 ((dd, 1 H, $J_{2-3} = 9.2$ Hz, $J_{2-1} = 3.8$ Hz, H-2), 3.88-3.62 (m, 5 H, H-3, H-4, H-5, H-6), 3.45 (s, 3 H, MeO), 2.28 (broad s, 1 H, OH). ¹³C NMR (75 MHz, CDCl₃), δ (ppm) = 138.4 (Cq Ar), 137.3 (Cq Ar), 129.0 (CH Ar), 128.4 (CH Ar), 128.3 (CH Ar), 128.0 (CH Ar), 127.7 (CH Ar), 126.0 (CH Ar), 101.3 (CH-7), 99.9 (CH-1), 82.0 (CH), 78.8 (CH), 74.8 (PhCH₂O), 72.3 (CH), 69.0 (CH₂-6), 62.6 (CH), 55.4 (MeO).




Methyl 3-*O*-Benzyl-4,6-*O*-benzylidene-2-*O*-(*p*-methoxybenzyl)- β -D-glucopyranoside (**11b**).

Sodium hydride (90 mg ; 1.46 equiv.) was added to a cooled solution (0 °C) of **11a** (0.959 g; 2.57 mmol) in DMF (5.5 mL) containing PMBCl (0.45 mL; 1.29 equiv.) and tetrabutylammonium iodide (12 mg). The reaction was stirred 3 h at ambient temperature and quenched cautiously with water (10 mL) and AcOEt (30 mL). Stirring was continued during 15 min and then the organic layer was separated, washed with water (4 x 20 mL), brine (10 mL), dried (MgSO₄), filtered and concentrated under reduced pressure to afford a pale viscous liquid which solidified on standing. The crude product was recrystallized from AcOEt/cyclohexane (1:5) to produced **11b** (640 mg; 50.5%) as a white solid. Mp = 114 °C. $[\alpha]_D^{20} = -38.1$ (c 1.17 in CHCl₃). Elemental analysis for C₂₉H₃₂O₇ (492.560): Calcd. C, 70.71; H, 6.55. Found : C, 70.83; H, 6.44. ¹H NMR (300 MHz, CDCl₃), δ (ppm) = 7.51-7.27 (m, 10 H, ArCH), 7.27 (d, 2 H, $J = 8.5$ Hz, meta CH of OPMB), 6.86 (d, 2 H, $J = 8.6$ Hz, ortho CH of OPMB), 5.55 (s, 1 H, H-7), 4.91 and 4.83 (AB system, 2 H, $J = 11.5$ Hz, $\Delta\nu = 20.3$ Hz, PhCH₂O), 4.79 and 4.63 (AB system, 2 H, $J = 12.0$ Hz, $\Delta\nu = 46.5$ Hz, MeOPhCH₂O), 4.54 (d, 1 H, $J_{1-2} = 3.7$ Hz, H-1), 4.27 (dd, 1 H, $J_{6e-6a} = 9.9$ Hz, $J_{6e-5} = 4.5$ Hz, H-6eq), 4.03 (dd, 1 H, $J_{3-4} = J_{3-2} = 9.3$ Hz, H-3), 3.82 (m, 1 H, H-5), 3.81 (s, 3 H, MeO of OPMB), 3.71 (dd, 1 H, $J_{6a-6e} = J_{6a-5} = 10.0$ Hz, H-6ax), 3.60 (dd, 1 H, $J_{4-5} = J_{4-3} = 9.3$ Hz, H-4), 3.54 (dd, 1 H, $J_{2-3} = 9.4$ Hz, $J_{2-1} = 3.7$ Hz, H-2), 3.40 (s, 3 H, MeO on C1). ¹³C NMR (75 MHz, CDCl₃), δ (ppm) = 159.4 (Cq Ar), 138.7 (Cq Ar), 137.4 (Cq Ar), 130.2 (Cq Ar), 129.8 (CH Ar), 128.9 (CH Ar), 128.3 (CH Ar), 128.2 (CH Ar), 128.0 (CH Ar), 127.6 (CH Ar), 126.0 (CH Ar), 113.8 (ortho CH Ar of OPMB), 101.3 (CH-7), 99.3 (CH-1), 82.1 CH-4), 78.7 CH-2), 78.6 CH-3), 75.3 (CH₂ of OBn), 73.4 (CH₂ of OPMB), 69.1 (CH₂-6), 62.3 CH-5), 55.4 (MeO on C1), 55.3 (MeO of OPMB).


References:

- (1) (a) Ferrier, R. J. *J. Chem. Soc., Perkin Trans. 1*, **1979**, 1455-1458. (b) Lopez, O. L.; Fernández-Bolaños, J. G.; Lillelund, V. H.; Bols, M. *Org. Biomol. Chem.* **2003**, *1*, 478-482.
- (2) (a) Blattner, R.; Furneaux, R. H.; Kemmitt, T.; Tyler, P. C.; Ferrier, R. J.; Tiden, A.-K. *J. Chem. Soc., Perkin Trans. 1* **1994**, 3411-3421. (b) Ferrier, R. J.; Prasit, P.; Gainsford, G. J. *J. Chem. Soc., Perkin Trans. 1* **1983**, 1629-1634.
- (3) This product was described in 76 % yield with AgF (see ref 1a) and was obtained here with a modified alternative using DBU (ref 3a-d) to eliminate the hydrogen iodide. Attempts elimination with tBuOK (see ref 3e,f) gave only starting material.
(a) Enright, P. M.; O'Boyle, K. M.; Murphy, P. V. *Org. Lett.* **2000**, 3929-3932. (b) O'Brien, J. L.; Tosin, M.; Murphy, P. V. *Org. Lett.* **2001**, 3353-3356, (c) McDonnell, C.; Cronin, L.; O'Brien, J. L.; Murphy, P. V. *J. Org. Chem.* **2004**, *69*, 3565-3568. (d) Adam, S. *Tetrahedron Lett.* **1988**, *29*, 6589-6592. (e) Ermolenko, M. S.; Shekharam, T.; Lukacs, G.; Potier, P. *Tetrahedron Lett.* **1995**, 2461-2464. (f) Imuta, S.; Ochiai, S.; Kuribayashi, M.; Chida, N. *Tetrahedron Lett.* **2003**, 5047-5051.
- (4) This product was obtained in 83% with HgCl₂ (ref 1a) or in 89% with Hg(OAc)₂. Blattner, R.; Ferrier, R. J.; Haines, S. R. *J. Chem. Soc., Perkin Trans. 1* **1985**, 2413-2416.
- (5) (a) Evans, M. E. *Carbohydr. Res.* **1972**, *21*, 473-475. (b) Holder, N. L.; Fraser-Reid, B. *Can. J. Chem.* **1973**, *51*, 3357-3365. (c) Ho, W. M.; Wong, H. N. C.; Navailles, L.; Destrade, C.; Nguyen, H. T. *Tetrahedron* **1995**, *51*, 7373-7388.
- (6) Preparation of methyl α -D-glucopyranoside which is available commercially, can be obtained from D-(+)-glucose (Helferich, B.; Schäfer, W. *Org. Syn. Coll. Vol. I* **1958**, 364-365).
- (7) (a) Pelyvas, I. F.; Lindhorst, T. K.; Streicher, H.; Thiem, J. *Synthesis* **1991**, 1015-1018. (b) Hicks, D. R.; Fraser-Reid, B. *Synthesis* **1974**, 203-203. (c) Munavu, R. M.; Szmant, H. H. *J. Org. Chem.* **1976**, *41*, 1832-1836.
- (8) Pozsgay, V.; Dubois, E. P.; Pannell, L. *J. Org. Chem.* **1997**, *62*, 2832-2846.
- (9) Detosylation with NaBH₄ in DMSO was used according the procedure in ref. 8. The same product was obtained by regioselective monobenylation with (Bu₃Sn)₂O. Dasgupta, F.; Garegg, P. J. *Synthesis* **1994**, 1121-1123 [mp = 176-177°C; [α] = +79 (c 1.2 CHCl₃)].


Molecule 1 (^1H NMR, 300 MHz, CDCl_3).




Molecule 1 (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule 1 (300 MHz; CDCl_3)





Molecule 2 (^1H NMR, 300 MHz, CDCl_3).




Molecule 2 (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **2** (300 MHz; CDCl₃)




Molecule **3** (^1H NMR, 300 MHz, CDCl_3).




Molecule **3** (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **3** (300 MHz; CDCl₃)




HMQC spectrum of molecule **3** (CDCl₃)




Molecule 4 (^1H NMR, 300 MHz, CDCl_3).




Molecule 4 (^{13}C NMR, 75 MHz, CDCl_3).





Molecule **5** (^1H NMR, 300 MHz, CDCl_3).




Molecule **5** (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **5** (300 MHz; CDCl₃).




HMQC spectrum of molecule **5** (CDCl₃).




HMBC spectrum of molecule **5** (300 MHz; CDCl₃).




Molecule **6** (^1H NMR, 300 MHz, CDCl_3).




Molecule **6** (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **6** (300 MHz; CDCl₃).




HMQC spectrum of molecule **6** (CDCl₃)




Molecule **7a** (^1H NMR, 300 MHz, CDCl_3).




Molecule **7a** (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **7a** (300 MHz; CDCl₃).




NOESY spectrum of molecule **7a** (300 MHz; CDCl₃).




HMQC spectrum of molecule **7a** (CDCl₃).





HMBC spectrum of molecule **7a** (CDCl₃).




Molecule **7b** (^1H NMR, 300 MHz, CDCl_3).




Molecule **7b** (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **7b** (300 MHz; CDCl₃).




HMQC spectrum of molecule **7b** (CDCl₃).




Molecule **7c** (^1H NMR, 300 MHz, CDCl_3).




Molecule **7c** (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **7c** (300 MHz; CDCl₃).




HMQC spectrum of molecule **7c** (CDCl₃).




NOESY spectrum of molecule **7c** (300 MHz; CDCl₃).




Molecule **8** (¹H NMR, 300 MHz, CDCl₃).




Molecule **8** (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **8** (300 MHz; CDCl_3).




NOESY spectrum of molecule **8** (300 MHz; CDCl₃).




HMQC spectrum of molecule **8** (CDCl₃).





HMBC spectrum of molecule **8** (300 MHz; CDCl₃).




Molecule **9** (¹H NMR, 300 MHz, CDCl₃).




Molecule **9** (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **9** (300 MHz; CDCl_3).





Molecule **10** (^1H NMR, 300 MHz, CDCl_3).




Molecule **10** (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **10** (300 MHz; CDCl₃).




HMQC spectrum of molecule **10** (CDCl₃).




HMBC spectrum of molecule **10** (CDCl₃).





Molecule **11** (^1H NMR, 300 MHz, CDCl_3).




Molecule **11** (^{13}C NMR, 75 MHz, CDCl_3).





COSY spectrum of molecule **11** (300 MHz; CDCl_3).




Molecule 11a (^1H NMR, 300 MHz, CDCl_3)




Molecule **11a** (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **11a** (300 MHz; CDCl_3).





HMQC spectrum of molecule **11a** (CDCl_3).




Molecule **11b** (^1H NMR, 300 MHz, CDCl_3).




Molecule **11b** (¹³C NMR, 75 MHz, CDCl₃).





COSY spectrum of molecule **11b** (300 MHz; CDCl₃).




NOESY spectrum of molecule **11b** (300 MHz; CDCl₃).





HMQC spectrum of molecule **11b** (CDCl₃).




Molecule 12 (^1H NMR, 300 MHz, CDCl_3).




Molecule **12** (^{13}C NMR, 75 MHz, CDCl₃).




COSY spectrum of molecule **12** (300 MHz; CDCl₃).




NOESY spectrum of molecule **12** (300 MHz; CDCl₃).




HMQC spectrum of molecule **12** (CDCl₃).




HMBC spectrum of molecule **12** (CDCl₃).




Molecule **13** (¹H NMR, 300 MHz, CDCl₃).




Molecule **13** (¹³C NMR, 75 MHz, CDCl₃).





COSY spectrum of molecule **13** (300 MHz; CDCl₃).




HMQC spectrum of molecule **13** (CDCl_3).




Molecule **14** (^1H NMR, 300 MHz, CDCl_3).




Molecule **14** (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **14** (300 MHz; CDCl_3).




HMQC spectrum of molecule **14** (CDCl₃).




Molecule **14a** (¹H NMR, 300 MHz, CDCl₃).





Molecule **14a** (^{13}C NMR, 75 MHz, CDCl_3).




Molecule **15** (^1H NMR, 300 MHz, CDCl_3).




Molecule **15** (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **15** (300 MHz; CDCl_3).




NOESY spectrum of molecule **15** (300 MHz; CDCl₃).




HMQC spectrum of molecule **15** (CDCl₃).





HMBC spectrum of molecule **15** (CDCl₃).




Molecule **16** (¹H NMR, 300 MHz, CDCl₃).




Molecule **16** (¹³C NMR, 75 MHz, CDCl₃).




COSY spectrum of molecule **16** (300 MHz; CDCl₃).




NOESY spectrum of molecule **16** (300 MHz; CDCl₃).




HMBC spectrum of molecule **16** (CDCl₃).





HMBC spectrum of molecule **16** (CDCl_3).




Molecule **17** (^1H NMR, 300 MHz, CDCl_3).




Molecule **17** (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **17** (300 MHz; CDCl_3).




NOESY spectrum of molecule **17** (300 MHz; CDCl₃).




HMBC spectrum of molecule **17** (CDCl₃).





HMBC spectrum of molecule **17** (CDCl₃).




Molecule **18** (¹H NMR, 300 MHz, CDCl₃).




Molecule **18** (¹³C NMR, 75 MHz, CDCl₃).




COSY spectrum of molecule **18** (300 MHz; CDCl₃).




NOESY spectrum of molecule **18** (300 MHz; CDCl₃).




HMQC spectrum of molecule **18** (CDCl₃).





HMBC spectrum of molecule **18** (CDCl₃).




Molecule **19** (¹H NMR, 300 MHz, CDCl₃).




Molecule **19** (^{13}C NMR, 75 MHz, CDCl_3).




COSY spectrum of molecule **19** (300 MHz; CDCl_3).



NOESY spectrum of molecule **19** (300 MHz; CDCl₃).



HMQC spectrum of molecule **19** (CDCl₃).



HMBC spectrum of molecule **19** (CDCl_3).

